SI0871616T1 - Process for the preparation of anti-malarial drugs - Google Patents

Process for the preparation of anti-malarial drugs

Info

Publication number
SI0871616T1
SI0871616T1 SI9630461T SI9630461T SI0871616T1 SI 0871616 T1 SI0871616 T1 SI 0871616T1 SI 9630461 T SI9630461 T SI 9630461T SI 9630461 T SI9630461 T SI 9630461T SI 0871616 T1 SI0871616 T1 SI 0871616T1
Authority
SI
Slovenia
Prior art keywords
preparation
malarial drugs
malarial
drugs
Prior art date
Application number
SI9630461T
Other languages
English (en)
Slovenian (sl)
Inventor
Cletus Onwuzurike SmithKline Beecham UGWUEGBULAM
James Edward SmithKline Beecham FOY
Original Assignee
Smithkline Beecham P.L.C.
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C., Smithkline Beecham Corporation filed Critical Smithkline Beecham P.L.C.
Publication of SI0871616T1 publication Critical patent/SI0871616T1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/40Nitrogen atoms attached in position 8
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI9630461T 1995-10-13 1996-10-11 Process for the preparation of anti-malarial drugs SI0871616T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9521004.3A GB9521004D0 (en) 1995-10-13 1995-10-13 Process
EP96934646A EP0871616B1 (en) 1995-10-13 1996-10-11 Process for the preparation of anti-malarial drugs
PCT/EP1996/004433 WO1997013753A1 (en) 1995-10-13 1996-10-11 Process for the preparation of anti-malarial drugs

Publications (1)

Publication Number Publication Date
SI0871616T1 true SI0871616T1 (en) 2002-12-31

Family

ID=10782264

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630461T SI0871616T1 (en) 1995-10-13 1996-10-11 Process for the preparation of anti-malarial drugs

Country Status (28)

Country Link
US (1) US6479660B1 (ar)
EP (1) EP0871616B1 (ar)
JP (1) JP4083803B2 (ar)
KR (1) KR100453256B1 (ar)
CN (1) CN1147475C (ar)
AR (1) AR004015A1 (ar)
AT (1) ATE214372T1 (ar)
AU (1) AU709333B2 (ar)
BR (1) BR9611010A (ar)
CA (1) CA2231633C (ar)
CZ (1) CZ290380B6 (ar)
DE (1) DE69619863T2 (ar)
DK (1) DK0871616T3 (ar)
ES (1) ES2170874T3 (ar)
GB (1) GB9521004D0 (ar)
HK (1) HK1016180A1 (ar)
HU (1) HUP9900739A3 (ar)
IL (1) IL124060A (ar)
NO (1) NO313285B1 (ar)
NZ (1) NZ320209A (ar)
PL (1) PL186055B1 (ar)
PT (1) PT871616E (ar)
SA (1) SA97170574B1 (ar)
SI (1) SI0871616T1 (ar)
TR (1) TR199800637T2 (ar)
TW (1) TW450950B (ar)
WO (1) WO1997013753A1 (ar)
ZA (1) ZA968550B (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08276712A (ja) * 1995-04-05 1996-10-22 Masao Tsuji チュ−ブレススパイクタイヤ
GB0210150D0 (en) 2002-05-03 2002-06-12 Smithkline Beecham Plc Process
WO2007032016A1 (en) * 2005-09-12 2007-03-22 Council Of Scientific And Industrial Research An antimalarial baylis-hillman adducts and a process for the preparation thereof
WO2007127930A2 (en) * 2006-04-28 2007-11-08 Kansas State University Research Foundation Compounds affecting gap junction activity
GB0620005D0 (en) 2006-10-10 2006-11-22 Glaxo Group Ltd Compounds
US20090076072A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched tafenoquine
ES2453206B1 (es) 2013-09-25 2015-01-12 Thyssenkrupp Elevator Innovation Center, S.A. Sistema de tracción para un sistema de transporte
CN113248431A (zh) * 2021-05-21 2021-08-13 重庆医药高等专科学校 一种磷酸伯氨喹的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431807A (en) * 1980-06-12 1984-02-14 The United States Of America As Represented By The Secretary Of The Army 4-Methyl-5-(unsubstituted and substituted phenoxy)-6-methoxy-8-(aminoalkylamino)quinolines
US4617394A (en) * 1985-10-15 1986-10-14 The United States Of America As Represented By The Secretary Of The Army 4-methyl-5-(unsubstituted and substituted phenoxy)-2,6-dimethoxy-8-(aminoalkylamino) quinolines

Also Published As

Publication number Publication date
ATE214372T1 (de) 2002-03-15
GB9521004D0 (en) 1995-12-13
EP0871616A1 (en) 1998-10-21
IL124060A (en) 2003-07-31
CZ110398A3 (cs) 1998-09-16
AU709333B2 (en) 1999-08-26
CN1199395A (zh) 1998-11-18
PL186055B1 (pl) 2003-09-30
NO981537D0 (no) 1998-04-03
CA2231633A1 (en) 1997-04-17
JP4083803B2 (ja) 2008-04-30
CN1147475C (zh) 2004-04-28
WO1997013753A1 (en) 1997-04-17
ES2170874T3 (es) 2002-08-16
NZ320209A (en) 1999-08-30
BR9611010A (pt) 1999-07-13
DE69619863T2 (de) 2002-11-21
SA97170574B1 (ar) 2006-09-25
CA2231633C (en) 2006-10-03
KR100453256B1 (ko) 2004-12-17
PT871616E (pt) 2002-07-31
HUP9900739A2 (hu) 1999-09-28
ZA968550B (en) 1998-04-14
PL326194A1 (en) 1998-08-31
HUP9900739A3 (en) 1999-11-29
KR19990064210A (ko) 1999-07-26
EP0871616B1 (en) 2002-03-13
CZ290380B6 (cs) 2002-07-17
TW450950B (en) 2001-08-21
AR004015A1 (es) 1998-09-30
DK0871616T3 (da) 2002-07-01
HK1016180A1 (en) 1999-10-29
TR199800637T2 (xx) 1998-07-21
AU7291096A (en) 1997-04-30
DE69619863D1 (de) 2002-04-18
JPH11513399A (ja) 1999-11-16
NO313285B1 (no) 2002-09-09
NO981537L (no) 1998-04-03
US6479660B1 (en) 2002-11-12

Similar Documents

Publication Publication Date Title
ZA961344B (en) Process for the preparation of thietanones
HUP9602957A2 (en) Process for the preparation of dihalo- and dihidroxi-azolopyrimidines
IL124768A0 (en) Novel pyridine compounds processes for their preparation and their use as pharmaceutical agents
SI0877738T1 (en) Process for the preparation of phenylimidazolidine derivatives
HK1016180A1 (en) Process for the preparation of anti-malarial drugs
HUP9903481A3 (en) Process for the preparation of 1-aryl-1-cyanocyclobutane derivatives
ZA962538B (en) Process for the preparation of dihydroartemisinin hemisucinate
IL118200A0 (en) Process for the preparation of substituted 2-fluoro-pyrimidines
ZA961050B (en) Substituted benzenesulfonylureas and -thioureas processes for their preparation their use for the production of pharmaceutical preparations and pharmaceutical preparations containing them
HRP960357B1 (en) Process for the preparation of lovastatin
IL115090A0 (en) Process for the preparation of p-bromofluorobenzene
IL118973A0 (en) Process for the preparation of substituted aminocarbonyltriazolinones
AU6738496A (en) Process for preparing solid dosage forms of very low-dose drugs
ZA963102B (en) Process for the preparation of streptogramins
HUP9601325A2 (en) Process for the preparation of optionally 2-substituted 5-chloroimidazole-4-carbaldehyde derivatives
HUP9901543A3 (en) Process for the preparation of hydroxysulfone derivatives
IL118732A0 (en) Process for the preparation of arylidene-substituted alkylcycloalkanones
IL118747A (en) Process for the preparation of 3-hydroxyoxetanes
EP0752419A3 (de) Verfahren zur Herstellung von N-substituierten 4-Ketoprolin-Derivaten
ZA965895B (en) Process for the preparation of alpha omega-bromochloro-alkanes
IL117065A0 (en) Process for the preparation of fluorocyclopropane derivatives
ZA96338B (en) Process for the preparation of (1-hydroxycyclohexane)- acetonitrile
IL148253A0 (en) Process for the preparation of 4-sulfanylpyrrolidin-2-yl
HK1009964A1 (en) Process for the preparation of dihaloazolopyrimidines
ZA969296B (en) New process for the preparation of morphinans